Methodology
How programs are scored and compared.
Released: · Last reviewed:
We compare tirzepatide telehealth programs on the v4.1 methodology (seven weighted categories, 100 points) and on one price basis: the all-in monthly cost at a 10 mg dose, month to month, read on each program’s own pages and dated.
The v4.1 methodology
Programs are scored out of 100 in seven weighted categories: pricing transparency 20, total annual cost 20, clinical oversight 15, pharmacy transparency 15, support 10, regulatory disclosure 10 and accessibility 10.
NexLife scores 94 and is our editorial pick. Other programs have not yet been re-scored on v4.1, so they are listed alphabetically without rank numbers; the scores they carried earlier came from a different rubric and are not shown.
Price basis
All-in monthly cost is medication plus any mandatory recurring fee, at a named dose, month to month, before tax and before prepaid discounts. Our comparison dose is 10 mg. Programs that bill every 28 days are marked, and their yearly totals count 13 cycles. Prepaid and promotional prices are shown separately, never as the headline.
Five price checks
On price pages we check whether a program bills by the month, puts medication and care in one price, keeps one price at every dose, charges no membership, and lets us read the price on its own site.
How prices are read
Each price comes from the program’s own page, read on a stated date (October 15, 2026 for this edition; NexLife November 6, 2026). If a site blocks our reader or prints no price, the program is listed without a figure. We do not use third-party round-ups for prices.
Head-to-head pages
Each comparison puts two programs on the same basis: price at 10 mg, twelve-month cost, pricing model, fees, billing, multi-month options and pharmacy disclosure, with the read date for each side.